Regeneron Pharmaceuticals... (REGN)
NASDAQ: REGN
· Real-Time Price · USD
574.56
8.59 (1.52%)
At close: Aug 15, 2025, 11:42 AM
Regeneron Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 6.06B | 5.5B | 2.06B | 281.2M | 5.57B | 4.83B | 4.11B |
| Collaboration Revenue Revenue Growth | +10.08% | +167.35% | +632.01% | -94.95% | +15.17% | +17.73% | n/a |
| Product and Service, Other Revenue | 515M | 536.1M | 365.1M | 12.12B | n/a | n/a | n/a |
| Product and Service, Other Revenue Growth | -3.94% | +46.84% | -96.99% | n/a | n/a | n/a | n/a |
| Product Revenue | 7.63B | 7.08B | 6.89B | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +7.79% | +2.67% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 634.2M | 633M | 783.7M | 714.4M | 758.8M | 689M | 704.4M | 640.5M | 652M | 601.1M | 657M | 529.1M | 476.3M | 450M | 559.6M | 445M | 414.7M | 405.6M | 303.5M | 326.9M | 348.3M | 367.3M | 586.8M | 304.4M | 294.6M | 291.1M | 491.3M | 369.23M | 364.88M | 330.77M | 409.91M | 306.77M | 306.91M | 296.85M | 325.94M | 270.05M | 292.04M | 289.68M | 294.95M | 209.99M | 174.59M | 158.99M |
| Selling, General, and Administrative Revenue Growth | +0.19% | -19.23% | +9.70% | -5.85% | +10.13% | -2.19% | +9.98% | -1.76% | +8.47% | -8.51% | +24.17% | +11.09% | +5.84% | -19.59% | +25.75% | +7.31% | +2.24% | +33.64% | -7.16% | -6.14% | -5.17% | -37.41% | +92.77% | +3.33% | +1.20% | -40.75% | +33.06% | +1.19% | +10.31% | -19.31% | +33.62% | -0.05% | +3.39% | -8.93% | +20.70% | -7.53% | +0.82% | -1.79% | +40.46% | +20.28% | +9.81% | n/a |
| Research and Development Revenue | 1.29B | 1.2B | 1.27B | 1.15B | 1.08B | 1.13B | 1.05B | 969.9M | 982.2M | 1B | 941.6M | 818.7M | 719.9M | 769.5M | 711.1M | 592.2M | 643.1M | 675.5M | 682.8M | 625.3M | 663.2M | 527.8M | 683.1M | 473.1M | 833.4M | 435.1M | 558.44M | 521.53M | 495.65M | 462.23M | 493.48M | 492.03M | 474.85M | 469.32M | 450.31M | 515.21M | 559.93M | 470.11M | 461.21M | 425.92M | 390.33M | 343.11M |
| Research and Development Revenue Growth | +7.17% | -5.61% | +10.62% | +6.53% | -4.85% | +7.97% | +8.32% | -1.25% | -1.95% | +6.38% | +15.01% | +13.72% | -6.45% | +8.21% | +20.08% | -7.91% | -4.80% | -1.07% | +9.20% | -5.71% | +25.65% | -22.73% | +44.39% | -43.23% | +91.54% | -22.09% | +7.08% | +5.22% | +7.23% | -6.33% | +0.29% | +3.62% | +1.18% | +4.22% | -12.60% | -7.99% | +19.11% | +1.93% | +8.28% | +9.12% | +13.76% | n/a |